Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Reynolds

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Medical and Pediatric Oncology|May 20, 1998
Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastomaS S Goldberg, K DeSantes, J P Huberty, et al.
Progress in Clinical and Biological Research|January 1, 1991
Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastomaR C Seeger, J G Villablanca, K K Matthay, et al.
Medical and Pediatric Oncology|December 7, 2000
Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastomaL M Choi, N W Kim, J J Zuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastomaK K Matthay, K DeSantes, B Hasegawa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group resultsK K Matthay, M C O'Leary, N K Ramsay, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 1996
Olfactory neuroblastoma is a peripheral primitive neuroectodermal tumor related to Ewing sarcomaP H Sorensen, J K Wu, K W Berean, et al.
The Journal of Clinical Investigation|July 1, 1991
High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplificationN Hailat, D R Keim, R F Melhem, et al.
Progress in Clinical and Biological Research|January 1, 1994
Comparison of autologous and allogeneic bone marrow transplantation for neuroblastomaK K Matthay, R C Seeger, C P Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer GroupK K Matthay, R C Seeger, C P Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology GroupW B London, R P Castleberry, K K Matthay, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Medical and Pediatric Oncology|May 20, 1998
Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastomaS S Goldberg, K DeSantes, J P Huberty, et al.
Progress in Clinical and Biological Research|January 1, 1991
Intensive chemoradiotherapy and autologous bone marrow transplantation for poor prognosis neuroblastomaR C Seeger, J G Villablanca, K K Matthay, et al.
Medical and Pediatric Oncology|December 7, 2000
Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastomaL M Choi, N W Kim, J J Zuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastomaK K Matthay, K DeSantes, B Hasegawa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group resultsK K Matthay, M C O'Leary, N K Ramsay, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 1996
Olfactory neuroblastoma is a peripheral primitive neuroectodermal tumor related to Ewing sarcomaP H Sorensen, J K Wu, K W Berean, et al.
The Journal of Clinical Investigation|July 1, 1991
High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplificationN Hailat, D R Keim, R F Melhem, et al.
Progress in Clinical and Biological Research|January 1, 1994
Comparison of autologous and allogeneic bone marrow transplantation for neuroblastomaK K Matthay, R C Seeger, C P Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1994
Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer GroupK K Matthay, R C Seeger, C P Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2005
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology GroupW B London, R P Castleberry, K K Matthay, et al.
Pageof 12